Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | APAF1 | O14727 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NSD2 | O96028 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23793110 | 0.95 | GRM5 (0.35) | NPC1RAB9AGRM5ALDH1A1MAPT | |
| SCHEMBL29741313 | 0.95 | GRM5 (0.35) | NPC1RAB9AGRM5ALDH1A1MAPT | |
| SCHEMBL29274083 | 0.90 | — | — | |
| SCHEMBL7708007 | 0.80 | HTR2C (0.42) | ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4136886 | 0.73 | NPC1 (0.48) | NPC1RAB9AALDH1A1KDM4EAPAF1 | |
| SCHEMBL29393274 | 0.73 | NPC1 (0.48) | NPC1RAB9AALDH1A1KDM4EAPAF1 | |
| SCHEMBL4136883 | 0.71 | NPC1 (0.37) | NPC1RAB9AALDH1A1KDM4EAPAF1 | |
| SCHEMBL31758711 | 0.71 | NPC1 (0.37) | NPC1RAB9AALDH1A1KDM4EAPAF1 | |
| SCHEMBL7421770 | 0.71 | NOS3 (0.45) | NPC1RAB9AALDH1A1KDM4EAPAF1 | |
| SCHEMBL24869475 | 0.71 | NPC1 (0.46) | NPC1RAB9AALDH1A1KDM4EAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241905-A1 | 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| CN-105051927-A | Azabenzimidazole carbene complexes as efficiency booster in OLEDs | BASF SE | 2015-11-11 | — | — | CN | disclosed |
| US-7407969-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-05 | — | — | US | disclosed |
| EP-1400519-B1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-03-07 | — | — | EP | disclosed |
| US-7071192-B1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-07-04 | — | — | US | disclosed |
| US-20060058309-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
| EP-1400519-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1196410-B1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2004-02-18 | — | — | EP | disclosed |
| EP-1196410-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000615-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
| US-5306819-A | Anxiolytic agents | NEUROGEN CORPORATION (US) | 1994-04-26 | — | — | US | disclosed |
| WO-1994005665-A1 | CERTAIN ARYL AND CYCLOALKYL FUSED IMIDAZOPYRAZINOLS; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058309-A1 | Respiratory syncytial virus replication inhibitors | NR4A1, NR4A3, NR4A2 | NPC1 2628/4885RAB9A 3324/4885GRM5 867/4885 |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | NPC1 327/4885RAB9A 255/4885GRM5 490/4885 |
| US-20250241905-A1 | 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | HSD3B1, HSD3B2, HSD17B11 | NPC1 500/4885RAB9A 4094/4885GRM5 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.